Scinai Immunotherapeutics Ltd. (SCNI) Form 6-K — Oct 20, 2026

$SCNIForm 6-KFiled Oct 20, 2026, 10:09 AM ET0001213900-26-110869Original filing

Scinai's CEO issued a shareholder letter detailing a new CDMO agreement with a U.S.-based, Nasdaq-listed biopharma company carrying approximately $5.1 million in committed base service fees, lifting Committed Customer Orders to roughly $8.1 million from $1.9 million at year-end 2025 — growth of more than 300%. Including uncommitted later-phase work with an indicative value of about $5.85 million, the total opportunity exceeds $10 million.

Key figures

Estimated runway: late 2027, potentially Q3 2028
Sepa net proceeds: $1.67 million
Total opportunity: exceeding $10 million
Combined net proceeds: $5.3 million
Private placement net: $3.6 million
Committed orders growth: more than 300%
Private placement gross: $4 million
Committed base service fees: $5.1 million
Committed customer orders ye 2025: $1.9 million
Committed customer orders oct 2026: $8.1 million
Indicative uncommitted later phases: $5.85 million

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.